• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

首个用于预测乳头状肾细胞癌患者的竞争风险生存诺莫图。

The first competing risk survival nomogram in patients with papillary renal cell carcinoma.

机构信息

Department of Urology, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.

Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, 710032, China.

出版信息

Sci Rep. 2021 Jun 4;11(1):11835. doi: 10.1038/s41598-021-91217-z.

DOI:10.1038/s41598-021-91217-z
PMID:34088935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8178392/
Abstract

There is still a lack of competing risk analysis of patients with papillary renal cell carcinoma (pRCC) following surgery. We performed the cumulative incidence function (CIF) to estimate the absolute risks of cancer-specific mortality (CSM) and other-cause mortality (OCM) of pRCC over time, and constructed a nomogram predicting the probability of 2-, 3- and 5-year CSM based on competing risk regression. A total of 5993 pRCC patients who underwent nephrectomy between 2010 and 2016 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. The 2-, 3-, 5-year CSM rates were 3.2%, 4.4% and 6.5%, respectively, and that of OCM were 3.2%, 5.0% and 9.3%, respectively. The estimates of 5-year cumulative mortality were most pronounced among patients aged > 75 years in OCM (17.0%). On multivariable analyses, age, tumor grade, T stage, N stage, and with or without bone, liver and lung metastases were identified as independent predictors of CSM following surgery and were integrated to generate the nomogram. The nomogram achieved a satisfactory discrimination with the AUC of 0.730 at 5-year, and the calibration curves presented impressive agreements. Taken together, age-related OCM is a significant portion of all-cause mortality in elderly patients and our nomogram can be used for decision-making and patient counselling.

摘要

对于接受手术治疗后的乳头状肾细胞癌(pRCC)患者,目前仍缺乏竞争风险分析。我们通过累积发生率函数(CIF)来估计患者的癌症特异性死亡率(CSM)和其他原因死亡率(OCM)的绝对风险,根据竞争风险回归构建预测 2 年、3 年和 5 年 CSM 概率的列线图。从监测、流行病学和最终结果(SEER)数据库中,我们确定了 2010 年至 2016 年间接受肾切除术的 5993 名 pRCC 患者。2 年、3 年和 5 年 CSM 率分别为 3.2%、4.4%和 6.5%,OCM 率分别为 3.2%、5.0%和 9.3%。在 OCM 中,年龄>75 岁的患者 5 年累积死亡率估计值最为显著(17.0%)。在多变量分析中,年龄、肿瘤分级、T 分期、N 分期以及是否有骨、肝和肺转移被确定为手术后 CSM 的独立预测因素,并将其整合到列线图中。该列线图在 5 年时的 AUC 为 0.730,具有良好的区分度,校准曲线显示出良好的一致性。总之,与年龄相关的 OCM 是老年患者全因死亡率的重要组成部分,我们的列线图可用于决策和患者咨询。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/84c100c0bb6f/41598_2021_91217_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/2d163b6c3f63/41598_2021_91217_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/de518a8f5d2b/41598_2021_91217_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/ed323a08e1a1/41598_2021_91217_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/1661a5074068/41598_2021_91217_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/e96696d180fb/41598_2021_91217_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/84c100c0bb6f/41598_2021_91217_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/2d163b6c3f63/41598_2021_91217_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/de518a8f5d2b/41598_2021_91217_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/ed323a08e1a1/41598_2021_91217_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/1661a5074068/41598_2021_91217_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/e96696d180fb/41598_2021_91217_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fd22/8178392/84c100c0bb6f/41598_2021_91217_Fig6_HTML.jpg

相似文献

1
The first competing risk survival nomogram in patients with papillary renal cell carcinoma.首个用于预测乳头状肾细胞癌患者的竞争风险生存诺莫图。
Sci Rep. 2021 Jun 4;11(1):11835. doi: 10.1038/s41598-021-91217-z.
2
A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.基于人群的肾细胞癌肾切除术后生存的竞争风险分析。
Urol Oncol. 2014 Jan;32(1):46.e1-7. doi: 10.1016/j.urolonc.2013.06.010. Epub 2013 Sep 17.
3
A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study.一种基于人群的研究:预测肾细胞癌患者肾切除术后总生存的新型列线图和风险分类系统。
Front Public Health. 2022 Oct 5;10:989566. doi: 10.3389/fpubh.2022.989566. eCollection 2022.
4
A Competing-Risks Nomogram in Patients with Metastatic Pancreatic Duct Adenocarcinoma.转移性胰腺导管腺癌患者的竞争风险列线图
Med Sci Monit. 2019 May 18;25:3683-3691. doi: 10.12659/MSM.913533.
5
A non-cancer-related survival benefit is associated with partial nephrectomy.部分肾切除术与非癌症相关的生存获益相关。
Eur Urol. 2012 Apr;61(4):725-31. doi: 10.1016/j.eururo.2011.11.047. Epub 2011 Dec 3.
6
Development and validation of prognostic nomograms for adult with papillary renal cell carcinoma: A retrospective study.开发和验证成人肾乳头状细胞癌预后列线图:一项回顾性研究。
Clinics (Sao Paulo). 2024 May 7;79:100374. doi: 10.1016/j.clinsp.2024.100374. eCollection 2024.
7
A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.基于人群的 T1A 期肾细胞癌行根治性肾切除术与部分肾切除术的肿瘤控制率比较。
Urology. 2010 Oct;76(4):883-8. doi: 10.1016/j.urology.2009.08.028.
8
Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years.比较部分肾切除术与根治性肾切除术对 75 岁以上患者其他原因死亡率、癌症特异性死亡率和 30 天死亡率的影响。
Eur Urol Focus. 2019 May;5(3):467-473. doi: 10.1016/j.euf.2018.01.007. Epub 2018 Feb 3.
9
Development and external validation of a nomogram predicting disease specific survival after nephrectomy for papillary renal cell carcinoma.建立并验证用于预测肾乳头状细胞癌患者肾切除术后疾病特异性生存的列线图。
J Urol. 2010 Jul;184(1):53-8. doi: 10.1016/j.juro.2010.03.026. Epub 2010 May 15.
10
A prognostic nomogram for the cancer-specific survival of patients with upper-tract urothelial carcinoma based on the Surveillance, Epidemiology, and End Results Database.基于监测、流行病学和最终结果数据库的上尿路上皮癌患者癌症特异性生存的预后列线图。
BMC Cancer. 2020 Jun 8;20(1):534. doi: 10.1186/s12885-020-07019-5.

引用本文的文献

1
Are We Accurately Predicting Mortality in Renal Cancer? A Systematic Review of Prognostic Models.我们是否准确预测了肾癌的死亡率?预后模型的系统评价。
J Clin Med. 2025 Aug 19;14(16):5851. doi: 10.3390/jcm14165851.
2
Dephosphorylation-related signature predicts the prognosis of papillary renal cell carcinoma.去磷酸化相关特征预测乳头状肾细胞癌的预后。
Transl Cancer Res. 2024 Nov 30;13(11):5983-5994. doi: 10.21037/tcr-24-669. Epub 2024 Nov 25.
3
Case report: Uncommon gastric metastasis as a presentation of recurrent clear cell renal cell carcinoma.

本文引用的文献

1
Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation.肿瘤分期和亚分期可预测非转移性肾癌肾切除术后的癌症特异性死亡率:组织学亚型特异性验证。
Eur Urol Focus. 2022 Jan;8(1):182-190. doi: 10.1016/j.euf.2021.02.009. Epub 2021 Feb 27.
2
Predictive Nomogram for Midterm to Long-Term Prognosis in Patients with Papillary Renal Cell Carcinoma Based on Data from the Surveillance, Epidemiology, and End Results (SEER) Program.基于监测、流行病学和最终结果(SEER)计划数据的乳头状肾细胞癌患者中期至长期预后预测列线图。
Med Sci Monit. 2020 Jun 22;26:e921859. doi: 10.12659/MSM.921859.
3
病例报告:罕见的胃转移作为复发性透明细胞肾细胞癌的一种表现。
Front Oncol. 2024 May 2;14:1354127. doi: 10.3389/fonc.2024.1354127. eCollection 2024.
4
A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study.一种基于人群的研究:预测肾细胞癌患者肾切除术后总生存的新型列线图和风险分类系统。
Front Public Health. 2022 Oct 5;10:989566. doi: 10.3389/fpubh.2022.989566. eCollection 2022.
5
Development and Validation of a Nomogram to Predict Cancer-Specific Survival in Elderly Patients With Papillary Renal Cell Carcinoma.预测老年乳头状肾细胞癌患者癌症特异性生存的列线图的开发与验证
Front Public Health. 2022 Apr 4;10:874427. doi: 10.3389/fpubh.2022.874427. eCollection 2022.
6
Predictive and Prognostic Assessment Models for Tumor Deposit in Colorectal Cancer Patients With No Distant Metastasis.无远处转移的结直肠癌患者肿瘤沉积物的预测和预后评估模型
Front Oncol. 2022 Feb 16;12:809277. doi: 10.3389/fonc.2022.809277. eCollection 2022.
Construction and validation of a novel prognostic nomogram for patients with sarcomatoid renal cell carcinoma: a SEER-based study.
构建和验证基于 SEER 数据库的肉瘤样肾细胞癌患者新型预后列线图模型。
Int J Clin Oncol. 2020 Jul;25(7):1356-1363. doi: 10.1007/s10147-020-01681-2. Epub 2020 May 2.
4
Development and validation of a prognostic nomogram for patients with intravesical recurrence after radical nephroureterectomy for non-metastatic upper tract urothelial carcinoma.根治性肾输尿管切除术治疗非转移性上尿路上皮癌患者膀胱内复发的预后列线图的建立和验证。
World J Urol. 2020 Aug;38(8):1969-1975. doi: 10.1007/s00345-019-02985-3. Epub 2019 Oct 25.
5
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.基于 ASSURE 前瞻性临床试验队列的非转移性乳头状肾细胞癌术后疾病复发预测的 VENUSS 预后模型:开发与评估。
BMC Med. 2019 Oct 3;17(1):182. doi: 10.1186/s12916-019-1419-1.
6
External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database.利用大型多中心数据库对用于预测乳头状肾细胞癌患者疾病特异性生存的术后列线图进行外部验证。
Int J Clin Oncol. 2020 Jan;25(1):145-150. doi: 10.1007/s10147-019-01530-x. Epub 2019 Aug 30.
7
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.欧洲泌尿外科学会肾癌指南:2019 年更新版。
Eur Urol. 2019 May;75(5):799-810. doi: 10.1016/j.eururo.2019.02.011. Epub 2019 Feb 23.
8
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
9
Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.预测肾细胞癌手术后的肿瘤学结果。
Eur Urol. 2018 May;73(5):772-780. doi: 10.1016/j.eururo.2018.01.005. Epub 2018 Feb 3.
10
Nomogram for survival analysis in the presence of competing risks.存在竞争风险时生存分析的列线图
Ann Transl Med. 2017 Oct;5(20):403. doi: 10.21037/atm.2017.07.27.